A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)
Study of Durvalumab Following Chemoradiotherapy in Women with Locally Advanced Cervical Cancer
Sponsor: AstraZeneca AB
Enrolling: Female Patients Only
IRB Number: AAAS3988
U.S. Govt. ID: NCT03830866
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: AstraZeneca AB (AstraZeneca) is doing this research to find out if durvalumab, when given with chemoradiotherapy will help to treat cervical cancer.
This study is closed
Investigator
Ana Tergas, MD
Do You Qualify?
Have you been diagnosed with cervical cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE